Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?

International Journal of Molecular Sciences

Amélie Lopès¹  Emilie Vazeille¹  Romain Villéger¹  Elisabeth Billard¹  Nicolas Barnich¹  Mathilde Bonnet¹  Johan Gagnière¹  Guillaume Carrier¹  Julie Veziant¹ 

[1] Microbes, Intestin, Inflammation et Susceptibilité de l’Hôte (M2iSH) UMR 1071 Inserm/Université Clermont Auvergne, USC-INRA 2018, CRNH Auvergne, F-63000 Clermont-Ferrand, France;

关键词: intestinal microbiota;    chemotherapy;    probiotics;    cancer;    radiotherapy;    anticancer treatment;    surgery;    microbiome;    adjuvant therapies;   

DOI  :  10.3390/ijms20184584

来源: DOAJ

【 摘 要 】

Recently, preclinical and clinical studies targeting several types of cancer strongly supported the key role of the gut microbiota in the modulation of host response to anti-tumoral therapies such as chemotherapy, immunotherapy, radiotherapy and even surgery. Intestinal microbiome has been shown to participate in the resistance to a wide range of anticancer treatments by direct interaction with the treatment or by indirectly stimulating host response through immunomodulation. Interestingly, these effects were described on colorectal cancer but also in other types of malignancies. In addition to their role in therapy efficacy, gut microbiota could also impact side effects induced by anticancer treatments. In the first part of this review, we summarized the role of the gut microbiome on the efficacy and side effects of various anticancer treatments and underlying mechanisms. In the second part, we described the new microbiota-targeting strategies, such as probiotics and prebiotics, antibiotics, fecal microbiota transplantation and physical activity, which could be effective adjuvant therapies developed in order to improve anticancer therapeutic efficiency.

【 授权许可】

Unknown